The possibility of hormone-mediated PSA derangement in prostate cancer treatment
Authors
Abstract:
Background: This study was designed to suggest the possibility of hormone-related derangement in salvage radiotherapy (SRT) after radical prostatectomy in terms of prostate-specific antigen (PSA) control. Materials and Methods: Among 160 consecutive prostate cancer patients who received radical prostatectomy, 34 with SRT between 2004 and 2012 were retrospectively reviewed. The numbers of patients with pathologic T3-T4 stage, Gleason score 8-10, and positive resection margin were 11 (32.4%), 10 (29.4%), and 17 (50.0%), respectively. Median SRT dose was 64.8 Gy (range, 52.9-70.0 Gy) with 1.8-2.3 Gy fractionations. Biochemical failure-free survival after SRT was counted and the median follow-up period was 32.5 months (range, 10-118 months). Results: After SRT, the median time for PSA to decrease to less than 0.2 ng/mL was four months (range, 0-25 months). The three-year survival rate was 60.3%. On univariate analysis, preferential hormone therapy (PHT) (p=0.022), higher PSA at SRT (p=0.005), and higher PSA after surgery (p=0.003) were related to a shorter biochemical survival period. On multivariate analysis, lower PSA at SRT (p=0.016), higher radiation dose (p=0.007), and non-PHT (p=0.046) suggested a consistent PSA control. Conclusion: According to these results, low PSA values by hormonal intervention need to be reconsidered with a different way to look at the relationship between the PSA and hormone therapy. SRT should be considered for postoperative salvage treatment regardless of the hormone-related PSA values.
similar resources
PSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
full textpsa in early diagnosis of prostate cancer
we report our experience with 124 patients were referred 70 our urology clinic in sina hospital for urinary retention. serum psa analyzed by using a monoclonal assay. all patients underwent digital rectal examination. the patients devided in 3 groups: group 1 (87 men) with a serum psa level less than 4 ng/ml, group 2 (26 men) with a serum psa level 4-10 ng/ml and group 3 (11 men) with a serum p...
full textPSA Recurrence of Prostate Cancer:
Today, because of prostate-specific antigen (PSA) screening, prostate cancer in most patients is detected earlier and at younger ages than in the past. Despite this early detection and after definitive therapy, whether by radical prostatectomy (RP) or radiation therapy (RT), a biochemical recurrence will develop within 10 years of treatment in about 35% of men.1,2 With about 230,000 cases of pr...
full textClinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
PURPOSE We analyzed the pattern of change in the free-to-total prostate-specific antigen (f/t PSA) ratio and the progression to castration-resistant prostate cancer (CRPC) in patients with advanced prostate cancer who received hormone treatment and whose PSA nadir was below 0.1 ng/ml. MATERIALS AND METHODS We retrospectively analyzed the medical records of 52 patients with advanced prostate c...
full textTreatment options in hormone resistant prostate cancer.
Prostate cancer is the most frequently diagnosed cancer in humans. An estimated 189000 men will be diagnosed with prostate cancer in the USA in 2002, and an estimated 30200 will die as a result of the disease [1]. It is predominantly diagnosed in older men and is rarely diagnosed in men under the age of 40 in contrast with the observation that microscopic prostate cancer is present in 80–100% o...
full textMy Resources
Journal title
volume 16 issue None
pages 243- 250
publication date 2018-04
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023